Skip to content
OpenCapital
Get started

Cumberland Pharmaceuticals CPIX Vibativ — Revenue

Other product segments

Kristalose
$3.12M-28.7%
Sancuso
$2.93M+29.8%
Talicia
$1.92M—
Caldolor
$896.71K-34.7%
Other revenue
$168.85K-94.6%
Acetadote
$66.67K+65.8%

Similar metrics at other companies

Amgen logo
AMGNVectibix — Total revenues
$287M+7.5%
Ligand Pharmaceuticals logo
LGNDCapvaxive — Total revenues and income
$1.97M+122%
HRO
HROWVEVYE — Revenue
$20.95M-2.6%
ICU Medical logo
ICUIVital Care — Revenue
$72.35M-58.0%
BioMarin Pharmaceuticals logo
BMRNVIMIZIM — Total revenues
$210.2M+11.6%
Alkermes logo
ALKSVivitrol — Revenue
$112.43M+11.3%

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+142%
Enterprise value$90.91M+212%
P/S2.3×+1.4×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%—

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio1×-0.3×

Where this comes from

Reported directly by Cumberland Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's vibativ — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's vibativ — revenue?
Cumberland Pharmaceuticals (CPIX) reported vibativ — revenue of $2.12M in Q1 2026.
How has Cumberland Pharmaceuticals's vibativ — revenue changed year-over-year?
Cumberland Pharmaceuticals's vibativ — revenue decreased by 29.4% year-over-year, from $3M to $2.12M.
What is the long-term trend for Cumberland Pharmaceuticals's vibativ — revenue?
Over 4 years (2021 to 2025), Cumberland Pharmaceuticals's vibativ — revenue has grown at a -1.3% compound annual growth rate (CAGR), from $11.7M to $11.11M.
What does vibativ — revenue mean?
Represents the total gross sales generated from the Vibativ product line before any deductions. This metric tracks the top-line performance of this specific specialty pharmaceutical asset within the company's acute care portfolio.